AlphaGene identifies prostate cancer marker:
This article was originally published in Clinica
AlphaGene has discovered a potential new marker for prostate cancer, which it claims may provide a more reliable test for the disease than the widely used prostate specific antigen marker. The new marker is a member of the human carcinoembryonic antigen (CEA) subgroup. Other CEA subgroup members are already used as biomarkers for colon cancer, says the Woburn, Massachusetts firm. AlphaGene is seeking partners for a co-operative research and development project using its marker.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.